HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Growth Factor Receptors

Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.
Also Known As:
Receptors, Growth Factor; Receptors, Growth Factors; Receptors, Trophic Factor; Trophic Factor Receptor; Factor Receptor, Growth; Factor Receptor, Trophic; Growth Factors Receptors; Receptor, Growth Factor; Receptor, Trophic Factor; Growth Factor Receptor; Trophic Factor Receptors
Networked: 2663 relevant articles (75 outcomes, 234 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Ciardiello, Fortunato: 11 articles (01/2019 - 06/2002)
2. Osborne, C Kent: 9 articles (11/2015 - 12/2003)
3. Schiff, Rachel: 9 articles (11/2015 - 12/2003)
4. Tortora, Giampaolo: 8 articles (12/2021 - 06/2002)
5. Emons, Günter: 7 articles (01/2017 - 01/2002)
6. Gründker, Carsten: 7 articles (01/2017 - 01/2002)
7. Rich, Jeremy N: 6 articles (01/2022 - 01/2005)
8. Cavenee, Webster K: 6 articles (12/2019 - 01/2005)
9. Mischel, Paul S: 6 articles (12/2019 - 07/2015)
10. Orfao, Alberto: 6 articles (07/2015 - 09/2009)

Related Diseases

1. Neoplasms (Cancer)
2. Colorectal Neoplasms (Colorectal Cancer)
3. Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
4. Breast Neoplasms (Breast Cancer)
5. Lung Neoplasms (Lung Cancer)
01/01/2020 - "This study aimed to explore the characteristics of TGFBR1-epidermal growth factor receptor (EGFR)-CTNNB1-CDH1 axis in regulating the invasion and migration in lung cancer. "
12/20/2017 - "随着低剂量螺旋计算机断层扫描(computed tomography, CT)广泛应用于早期肺癌筛查,诊断出的双肺同时多发性病变的病例数逐年增多,且大多数病例最后证实为同时性多原发肺癌(synchronous multiple primary lung cancer, SMPLC)。既往研究结果显示SMPLC的发病率约为0.2%-8%(穿刺研究结果为3.5%-14%)。目前对于MPLC的诊断,大多依据Martini-Melamed的诊断标准:SMPLC:①肺癌部位各异,彼此孤立;②组织学类型不同;③组织学类型相同时,位于不同肺段、肺叶、不同侧肺,由不同的原位癌起源,肺癌共同的淋巴引流部位无癌肿,确立诊断时无肺外转移。异时性多原发肺癌(metachronous multiple primary lung cancer, MMPLC):①组织学类型不同;②组织学类型相同时,无瘤间期至少2年,或均由不同的原位癌起源,或第二原发癌位于不同肺叶或不同侧肺时,肺癌共同的淋巴引流部位无癌肿,确立诊断时无肺外转移。而各个肿瘤具有独特的病理形态特征为诊断MPLC的要点。此后很多学者在这条标准的基础上进行了不断的修订与丰富,包括国际肺癌研究协会(International Association for the Study of Lung Cancer, IASLC)新版肺腺癌分类及表皮生长因子受体(epidermal growth factor receptor, EGFR)、K-ras基因突变等,这些内容的增加使多原发癌灶与转移灶的鉴别诊断标准更加合理准确,也同时说明对于MPLC的各个病灶分别进行基因检测具有重要的鉴别和治疗意义。现将我院胸外科术后病理证实为不同组织亚型、不同基因型的同时性四原发肺癌患者诊治情况报道如下。."
08/01/2006 - "To study the mutation patterns of epithelial growth factor receptor (EGFR) exon 18, 19 and 21 in Chinese non-small-cell lung cancers (NSCLC). "
07/01/2023 - "18F-FDG-PET/CT in lung cancer predicted the mutation status of epidermoid growth factor receptor (EGFR). "
05/20/2022 - "【中文题目:EGFR外显子20插入突变阳性NSCLC治疗的临床研究进展】 【中文摘要:表皮生长因子受体(epidermal growth factor receptor, EGFR)外显子20插入突变是EGFR突变的第三大常见类别,约占所有EGFR突变阳性非小细胞肺癌(non-small cell lung cancer, NSCLC)的5%-12%。携带EGFR外显子20插入突变的NSCLC患者临床特征与“经典”EGFR激活突变人群相似,但预后很差。EGFR外显子20插入突变异质性高,可导致EGFR不同构象变化。大多数(几乎90%的病例)发生在α-C-螺旋后的Loop环结构区,最常报告的插入突变亚型为D770_N771>ASVDN(A767_V769dupASV),突变频率为21%-28%。目前已知EGFR外显子20插入突变的NSCLC对既往已批准的EGFR酪氨酸激酶抑制剂原发性耐药,而且对传统化疗和免疫治疗也不敏感。近期Amivantamab与Mobocertinib在美国的获批改变了EGFR外显子20插入突变的NSCLC患者的治疗模式。此外,针对NSCLC EGFR外显子20插入突变的其他新型靶向药物正在研发中,期待为该类患者带来更多生存获益。本文就近年来伴有EGFR外显子20插入突变的NSCLC的临床研究进展进行归纳总结,旨在为该类患者的临床治疗提供参考。】 【中文关键词:肺肿瘤;表皮生长因子受体;EGFR外显子20插入突变;靶向治疗】."

Related Drugs and Biologics

1. Tyrosine Kinase Inhibitors
2. Monoclonal Antibodies
3. Phosphotransferases (Kinase)
4. Cetuximab (Erbitux)
5. Panitumumab (Vectibix)
6. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
7. Trastuzumab (Herceptin)
8. Cytokines
9. Antibodies
10. Carrier Proteins (Binding Protein)

Related Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
3. Radiotherapy
4. Immunotherapy
5. Precision Medicine